|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/19 | |
| A61K 31/4412 | |||
| A61K 35/768 | |||
| A61P 35/04 | |||
| A61K 31/44 |
| (11) | Patento numeris | 2477499 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10816293.4 |
| Europos patento paraiškos padavimo data | 2010-09-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-07-25 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-04-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/048829 |
| Data | 2010-09-14 |
| (87) | Numeris | WO 2011/032180 |
| Data | 2011-03-17 |
| (30) | Numeris | Data | Šalis |
| 242238 P | 2009-09-14 | US | |
| 244250 P | 2009-09-21 | US |
| (72) |
KIRN, David, US
BREITBACH, Caroline, US
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
|
| (54) | ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |
| ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |